NEW YORK (GenomeWeb) – SpeeDx has announced a distribution agreement with Diagen, a Scandinavian clinical laboratory supplier.
The agreement will open crucial sales channels in Denmark, Sweden, and Norway for SpeeDx's PlexPCR and ResistancePlus real-time PCR product lines.
Using SpeeDx's technology, the PlexPCR range will enable Diagen customers to receive diagnostic information on STIs and other infectious diseases from a single test. The agreement will also provide Diagen customers access to SpeeDx's ResistancePlus MG assay, which tests for the Mycoplasma genitalium STI. SpeeDx's assay is the first CE-IVD test to simultaneously detect M. genitalium and genetic markers for azithromycin resistance, as recommended by new European guidelines on M. genitalium resistance screening in the management of non-gonococcal urethritis.
SpeeDx announced yesterday that the New South Wales Medical Devices Fund has granted the company A$2.5 million (US$2 million) for the continued rollout of the ResistancePlus MG test.